Introduction: Subthalamic nucleus (STN) deep brain stimulation (DBS) is recognized as a safe and effective treatment in mid- and advanced-staged Parkinson's disease (PD) that decreases the need for PD medications and their associated costs.

Grace Cannard K, Hacker M, Molinari A, E Heusinkveld L, Currie AD, Charles D. Recruitment and Retention in Clinical Trials of Deep Brain Stimulation in Early-Stage Parkinson's Disease: Past Experiences and Future Considerations.

0 Followers, 851 Following, 213 Posts - See Instagram photos and videos from @grace_cannard

View the profiles of people named Grace Cannard. Join Facebook to connect with Grace Cannard and others you may know. Facebook gives people the power to...

Grace Cannard is on Facebook. Join Facebook to connect with Grace Cannard and others you may know. Facebook gives people the power to share and makes the world more open and connected.

Objective: To assess the feasibility of recruitment in a future deep brain stimulation (DBS) in early-stage Parkinson's disease (PD) multicenter trial by understanding motivations and concerns to participation of past and potential future DBS in early-stage PD clinical trial subjects.

2021年11月1日 · Subthalamic nucleus (STN) deep brain stimulation (DBS) in mid- and advanced-staged Parkinson’s disease (PD) is a well-known procedure that improves quality of life, controls motor symptoms, and reduces levodopa-associated complications, which also decreases the need for PD medications and their associated costs [1], [2], [3], [4].

2021年11月1日 · Subthalamic nucleus (STN) deep brain stimulation (DBS) in mid- and advanced-staged Parkinson’s disease (PD) is a well-known procedure that improves quality of life, controls motor symptoms, and reduces levodopa-associated complications, which also decreases the need for PD medications and their associated costs [1], [2], [3], [4].

M. Hacker, Grace Cannard, +6 authors David K Charles; Published in Clinical neurology and… 8 October 2021; Medicine